Pharmaceutical - Asia-Pacific, Eli Lilly


Current filters:

Asia-PacificEli Lilly

Popular Filters

India’s patents moves could see particular uncertainty for diabetes sector

India’s patents moves could see particular uncertainty for diabetes sector


The Indian government's decision to review patented drugs by multinationals, to allow for the manufacture…

Abbott LaboratoriesAsia-PacificDiabetesEli LillyIndiaMarkets & MarketingMerck & CoNovo NordiskPatentsPharmaceutical

New Zealand views access to sugammadex and atomoxetine and baclofen injection funding


New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on the following proposals…

Asia-PacificBridionEli LillyLioresal IntrathecalMerck & CoNeurologicalNew ZealandPharmaceuticalRegulationStrattera

Trajenta studies prove efficacy in broad range of diabetes patients

Trajenta studies prove efficacy in broad range of diabetes patients


Boehringer Ingelheim and Eli Lilly (NYSE: LLY) have released new data that reinforces the efficacy and…

Asia-PacificBoehringer IngelheimDiabetesEli LillyNorth AmericaPharmaceuticalResearchTrajentaUSA

Cardiovascular risk a concern when prescribing diabetes treatments, survey finds


Boehringer Ingelheim and Eli Lilly (NYSE: LLY) revealed that 79% of nearly 800 physicians in four Asian…

Asia-PacificBoehringer IngelheimDiabetesEli LillyHealthcarePharmaceuticalResearch

Through 2022, growth in the neuropathic pain drug market will be constrained by generics


The loss of US and European market exclusivity of three sales-leading neuropathic pain (NP) agents -…

Asia-PacificCymbaltaEli LillyEndo PharmaceuticalsEuropeLidodermLyricaMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceutical

Lilly acquires rights to Hutchison MediPharma cancer drug candidate

Lilly acquires rights to Hutchison MediPharma cancer drug candidate


Hutchison MediPharma, an R&D company majority owned by China’s Chi-Med, has entered into a licensing,…

Asia-PacificEli LillyfruquintinibHutchison MediPharmaLicensingOncologyPharmaceutical

Eli Lilly latest to become embroiled in China bribery allegations


In the ongoing allegations of bribery and corruption by multinational drugmakers in China, US pharma…

Asia-PacificEli LillyLegalMarkets & MarketingPharmaceutical

Daiichi Sankyo files for Japanese approval of Prasugrel


Japanese drug major Daiichi Sankyo (TYO: 4568) says that it has submitted a New Drug Application to the…

Asia-PacificCardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelRegulation

Chinese diabetes market worth $2.2 billion, with over 50% accounted for by insulin


Demand within the Chinese insulin market has grown at a fast pace in the past decade. Over the next five…

Asia-PacificDiabetesEli LillyMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Nexavar use in Chinese patients nearly doubled in 2012


Use of Nexavar (sorafenib, from Bayer [BAYN: DE] and Onyx Pharmaceuticals) has nearly doubled in first-line…

AlimtaAsia-PacificBayerBiotechnologyEli LillyMarkets & MarketingNexavarOncologyPharmaceutical

Eli Lilly and Chugai to stop co-marketing of Evista in Japan


The Japanese subsidiary of US drug major Eli Lilly (NYSE: LLY) and Roche's (ROG: SIX) majority-owned…

Anti-Arthritics/RheumaticsAsia-PacificChugai PharmaceuticalEli LillyEvistaLicensingMarkets & MarketingPharmaceutical

Lilly to increase equity position in China's Novast by $20 million


US pharma major Eli Lilly (NYSE: LLY) says it will increase of its network of manufacturing capabilities…

Asia-PacificEli LillyGenericsMergers & AcquisitionsNovast LaboratoriesPharmaceutical

New Zealand approves Effient listing for clopidogrel-allergic patients


The Pharmaceutical Management Agency of New Zealand, PHARMAC, has announced reaching agreement with US…

Asia-PacificCardio-vascularEffientEli LillyPharmaceuticalPricingRegulation

Proposal to fund Lilly’s Effient in New Zealand


PHARMAC, the Pharmaceutical Management Agency of New Zealand, is seeking feedback on a proposal to fund…

Asia-PacificEffientEli LillyPharmaceuticalPricingRegulation

ShangPharma milestone in Hengrui accord; expands Lilly contract


Leading Chinese R&D outsourcing firm ShangPharma Corp (NYSE: SHP) says that it has reached the first…

Asia-PacificEli LillyJiangsu Hengrui MedicinePharmaceuticalResearchShangPharma

Back to top